Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
- Previous Close
19.78 - Open
19.97 - Bid 19.79 x --
- Ask 19.81 x --
- Day's Range
19.71 - 19.94 - 52 Week Range
16.32 - 29.21 - Volume
4,402,457 - Avg. Volume
7,408,491 - Market Cap (intraday)
10.372B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
33.02 - EPS (TTM)
0.60 - Earnings Date --
- Forward Dividend & Yield 0.29 (1.44%)
- Ex-Dividend Date Jan 10, 2025
- 1y Target Est
29.00
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; Changdian, a dust mite skin prick diagnostic kit; and Changdian II, a house dust mite skin prick diagnosis kit. It also involved in the research and development of stem cells and medical artificial intelligence solutions. The company was founded in 2002 and is headquartered in Huzhou, China.
www.wolwobiotech.com1,679
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300357.SZ
View MorePerformance Overview: 300357.SZ
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300357.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300357.SZ
View MoreValuation Measures
Market Cap
10.36B
Enterprise Value
9.08B
Trailing P/E
32.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.05
Price/Book (mrq)
4.27
Enterprise Value/Revenue
9.68
Enterprise Value/EBITDA
25.07
Financial Highlights
Profitability and Income Statement
Profit Margin
33.59%
Return on Assets (ttm)
7.39%
Return on Equity (ttm)
12.29%
Revenue (ttm)
937.62M
Net Income Avi to Common (ttm)
314.96M
Diluted EPS (ttm)
0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
1.29B
Total Debt/Equity (mrq)
0.41%
Levered Free Cash Flow (ttm)
83.8M